Intrommune Therapeutics Receives Formulation Patent Notice of Allowance
21 août 2019 14h41 HE
|
Intrommune Therapeutics
New York, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is...
Celsion Announces Publication of Results of National Institutes of Health (NIH) Analysis of ThermoDox® in Journal of Vascular and Interventional Radiology
13 août 2019 08h00 HE
|
Celsion CORP
NIH’s Independent Analysis of Celsion’s Phase III HEAT Study Confirms Increasing Radiofrequency Ablation (RFA) Heating Time + ThermoDox® Improves Overall Survival with Significance in Patients with...
Celsion's GEN-1 Immunotherapy Highlighted in Oppenheimer's Expert Call on Ovarian Cancer Treatment Landscape and Emerging Opportunities
09 août 2019 08h30 HE
|
Celsion CORP
Presentation Slides Available on Celsion’s Website LAWRENCEVILLE, N.J, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces that...
Aquinox Pharmaceuticals and Neoleukin Therapeutics announce merger agreement
06 août 2019 07h00 HE
|
Aquinox Pharmaceuticals, Inc.
• Combined company capitalized with approximately $65M to develop novel immunotherapies • Sophisticated computational platform enables new class of de novo protein therapeutics • Lead program,...
Incysus Therapeutics Strengthens Board of Directors With Appointment of Pharmaceutical Veteran Peter C. Brandt
06 août 2019 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Harpoon Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
05 août 2019 16h05 HE
|
Harpoon Therapeutics
Continued enrollment and dose escalation of Phase 1 trial for HPN424, Harpoon’s lead TriTAC product candidate in development for the treatment of prostate cancerInitiated Phase 1/2a clinical trial for...
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
31 juil. 2019 16h05 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
VBI Vaccines Announces Dosing of First Recurrent GBM Patient in Part B of Ongoing Phase 1/2a Study of VBI-1901
29 juil. 2019 08h00 HE
|
VBI Vaccines, Inc.
— Part B of the study, a subsequent extension of the optimal dose from Part A, to enroll 10 first-recurrent GBM patients— Initial immunologic data from Part B expected around year-end 2019— Expanded...
Colorectal Cancer Market To Cross USD 18 billion by 2023 | Reports And Data
24 juil. 2019 09h59 HE
|
Reports and Data
New York, July 24, 2019 (GLOBE NEWSWIRE) -- This report on the Colorectal Cancer market offers an extensive analysis of the trends to estimate its growth in the near future. It provides historical...
Therapeutic Solutions International Develops Glucoraphanin + NanoStilbene Encapsulated product for reduction of Prostate Specific Antigen (PSA)
08 juil. 2019 09h00 HE
|
Therapeutic Solutions International, Inc.
OCEANSIDE, Calif., July 08, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI) announced today the development of a broccoli sprout extract...